![TuHURA Biosciences Inc](/common/images/company/N_HURA.png)
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.39 | -30.0215982721 | 4.63 | 4.77 | 3.2 | 221760 | 4.05951182 | CS |
4 | -1.46 | -31.0638297872 | 4.7 | 5.27 | 3.2 | 207126 | 4.57668138 | CS |
12 | -0.76 | -19 | 4 | 7.2 | 3.2 | 386933 | 5.13275988 | CS |
26 | -3.31 | -50.534351145 | 6.55 | 7.93 | 2.92 | 282240 | 5.08997574 | CS |
52 | -3.31 | -50.534351145 | 6.55 | 7.93 | 2.92 | 282240 | 5.08997574 | CS |
156 | -3.31 | -50.534351145 | 6.55 | 7.93 | 2.92 | 282240 | 5.08997574 | CS |
260 | -3.31 | -50.534351145 | 6.55 | 7.93 | 2.92 | 282240 | 5.08997574 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約